Jasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants

The expected cash payment would purchase approximately 68.94% of the outstanding warrants covered by the offer.

Rhea-AI Summary

Jasper Therapeutics (JSPR) announced results of its cash offer to purchase outstanding warrants, with 8,510,658 warrants properly tendered and not withdrawn.

The tendered warrants represent approximately 68.94% of outstanding warrants covered by the offer. The purchase price is $0.324 in cash per warrant, without interest. Jasper expects to pay an aggregate of $2,757,453.19, with payment to be made promptly. The offer expired at 12:00 a.m., Eastern Time on November 7, 2026, and covered warrants issued in the September 18, 2025 underwritten public offering.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointWarrant repurchase attracted 8,510,658 properly tendered warrants, approximately 68.94% of outstanding warrants covered by the offer.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.Warrant purchases require an expected $2,757,453.19 cash payment at $0.324 per warrant, without interest. 15% of market cap

News Explained

With the offer expired, Jasper expects to pay $2,757,453.19 for 8,510,658 warrants—rights to buy common shares—so tendering holders exchange those potential share-purchase rights for cash.

Argus 15 min delay 7 alerts

-9.43% vs previous close $15.27 last price 0.2x rel. volume Open Argus

Details

Market move: JSPR -9.43% vs previous close. warrant tender offer results

$14.27 – $17.75 Day Range

$16.95M Mkt Cap at Last Price

On Nov 9, the day this news came out, the latest delayed price for JSPR is 9.43% below the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $15.27.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Purchase price per warrant: $0.324 in cash per Warrant Warrants tendered: 8,510,658 Warrants Share of outstanding warrants tendered: Approximately 68.94% +1 more

Purchase price per warrant

$0.324 in cash per Warrant

Offer to purchase

Warrants tendered

8,510,658 Warrants

Properly tendered and not properly withdrawn

Share of outstanding warrants tendered

Approximately 68.94%

Properly tendered and not properly withdrawn

Aggregate cash payment

$2,757,453.19

Expected payment in exchange for tendered Warrants

Historical Context

1 past event · Latest: Oct 07

1 event

1. Oct 07

   Warrant tender offer

   24h Move

   +1.7%

   Opened a cash offer for outstanding warrants at $0.324 each, with expiration scheduled for November 6.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

warrants, tender offer, schedule to, letter of transmittal

4 terms

warrants financial

"all of its outstanding warrants to purchase shares of its common stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

tender offer financial

"results of its offer to purchase (the “Offer”) all of its outstanding warrants"

A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.

View in glossary

schedule to regulatory

"tender offer statement on Schedule TO originally filed with the SEC"

A phrase indicating that a company plans or intends to hold an event, publish information, or take an action at a specified future time, but that the timing is not guaranteed and may change. For investors it signals an expected milestone—like an earnings call, product launch, or filing—so think of it as a calendar note rather than a firm promise; timing shifts can affect trading, expectations, and planning.

View in glossary

letter of transmittal financial

"an Offer to Purchase and Letter of Transmittal"

A letter of transmittal is a written form investors use when sending physical stock certificates or electronic ownership documents to a company or its agent to surrender shares, tender them in an offer, or claim payment or replacement securities. It acts like a packing slip that lists what is enclosed, gives instructions on how the transfer should be handled, and provides proof of the transaction—important for ensuring investors receive the correct payment or new securities without delay or dispute.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the results of its offer to purchase (the “Offer”) all of its outstanding warrants to purchase shares of its common stock, par value $0.0001, which were issued and sold as part of an underwritten public offering on September 18, 2025 (the “Warrants”) at a purchase price of $0.324 in cash per Warrant, without interest, which expired at 12:00 a.m., Eastern Time on November 7, 2026.

The Company has been advised that a total of 8,510,658 Warrants were properly tendered and not properly withdrawn, which amount represents approximately 68.94% of the outstanding Warrants. Pursuant to the terms of the Offer, the Company expects to pay an aggregate of $2,757,453.19 in cash in exchange for such Warrants. Such payment will be made promptly.

The Offer was made pursuant to an Offer to Purchase and Letter of Transmittal, and certain other materials contained in the Company’s tender offer statement on Schedule TO originally filed with the SEC on October 7, 2026, as amended from time to time (the “Offer to Purchase”).

All questions concerning the Offer should be directed to Jasper at (650) 549-1400.

This announcement is for informational purposes only and shall not constitute an offer to purchase or a solicitation of an offer to sell the Warrants. The Offer and Consent Solicitation were made only through the Schedule TO and Offer to Purchase.

About Jasper

Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including vensobafusp alfa, briquilimab, and KP701. Vensobafusp alfa is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant in severe combined immunodeficiencies (SCID), Fanconi anemia, as well as mast cell mediated diseases such as the chronic urticarias. KP701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.

Forward-Looking Statements

Certain statements contained in this press release are or may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate,” “potential,” “projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. Jasper cautions that these statements are based upon the current beliefs and expectations of Jasper’s management and are subject to significant risks, uncertainties and assumptions, including, without limitation, the uncertainties associated with the Company’s product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; risks that initial, interim or topline results from early-stage or open-label studies, including results in a limited number of patients, may not be predictive of, and may differ materially from, results from later stages of the same study or from later-stage or larger trials; risks related to the inability of the Company to obtain sufficient additional capital to continue to advance product candidates and its preclinical programs; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks associated with the possible failure to realize certain anticipated benefits of the merger with Kira Pharmaceuticals, including with respect to future financial and operating results; and such additional risks and uncertainties contained in the “Risk Factors” section of Jasper’s Annual Reports on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that Jasper has subsequently filed or may subsequently file with the SEC. Statements regarding future actions, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company’s formulations and product candidates and regulatory filings related to the same, financial projections and targets, including, without limitation, cash runway, operating plans, future capital requirements and the sufficiency of existing cash resources, business strategy, plans and objectives for future operations, statements regarding the Company and its operations and prospects, may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. There is no obligation to update publicly or revise any forward-looking statements for any reason after the date of this press release or to conform these statements to actual results or to changes in the Company’s expectations, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws.

Contacts:

Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertx.com

Argot Partners (investors and media)
kira@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were the results of Jasper Therapeutics' warrant purchase offer?

A total of 8,510,658 warrants were properly tendered and not properly withdrawn, representing approximately 68.94% of outstanding warrants covered by the offer. Jasper expects to pay $2,757,453.19 in aggregate at $0.324 in cash per warrant, without interest, with payment to be made promptly.